in medium- and high-risk areas was observed only in 1.20%. Previously published articles have reported a cure rate of more than 95% for BCC treated with CE when it is performed by experts and suitable selection criteria are applied. In summary, our experience is that CE can be a very effective and inexpensive technique for treating BCC, not only on low-risk areas but also on medium- and high-risk areas if: a) it is performed by experts; and b) suitable selection is performed (primary, nonfibrosing BCC with the diameters stated above). As with any other procedure, proper training is a crucial factor in its effectiveness and should always be borne in mind in the comparison of results between different techniques.

References

T. Rodríguez-Vigil, F. Vázquez-López,* N. Pérez-Oliva
Servicio de Dermatología, Hospital Universitario Central de Asturias, Oviedo, Spain
*Corresponding author.
E-mail address: fvlopez@telecable.es (F. Vázquez-López).
doi:10.1016/j.adengl.2011.01.005

We recently saw 2 cases of malignant melanoma with epidermal effacement. The first was a superficial spreading melanoma (SSM), located on the right arm, that had entered the vertical growth phase (Breslow depth of 0.95 mm and Clark level III) (Fig. 1). The second was also a SSM in the vertical growth phase (Breslow depth of 1.87 mm and Clark level IV) but located on the abdomen (Fig. 2). The tumors had been removed from a 51-year-old and a 50-year-old man, respectively.

It has been postulated that epidermal effacement is the result of an autoimmune or immunologic process as this histologic feature has also been seen in certain halo nevi (pseudo-epidermal effacement). Walters et al do not believe this to be the case as they found no association between epidermal effacement and either tumor regression or inflammatory infiltrates. It might also be a physical phenomenon related to the compression caused by tumor growth; this, however, would not explain why epidermal effacement is a relatively common finding in melanomas (found by Hantschke et al and Walters et al in 86% and 43% of cases, respectively), very few studies have analyzed it. Furthermore, we believe that this histologic feature is unfamiliar to the majority of dermatologists.

Figure 1 Epidermal effacement overlying malignant melanoma (hematoxylin-eosin, original magnification ×100).
effacement is found in some thin melanomas (with a low Breslow depth) or indeed why it is not found in the vast majority of thick melanomas. Epidermal effacement has also been seen in areas adjacent to melanoma ulceration as well as in association with fissures, clefting, and areas of dermal-epidermal separation, explaining why numerous studies have suggested that this histologic feature might be a marker of subsequent progression to ulceration. 1–4 In support of this theory, we have seen epidermal effacement in several epidermotropic metastatic melanomas.

Further studies are necessary to determine whether epidermal effacement, like ulceration, is associated with poorer prognosis in melanoma. 5,6 Moreover, epidermal effacement is observed more frequently in association with other indicators of poorer prognosis in malignant melanomas 5,6: increasing Breslow depth, number of mitoses per field, ulceration, and vertical growth. 2 Until it is determined whether or not epidermal effacement, like ulceration, is associated with poorer prognosis, we believe that it should be included in protocols for melanoma histopathology reports. 7 It is also interesting to note that paratumoral epidermal hyperplasia, which is precisely the opposite of epidermal effacement, located in zones adjacent to melanoma is associated with better prognosis in thick melanomas. 8

The question remains as to why epidermal effacement and ulceration occur in certain malignant melanomas independently of tumor duration, Breslow depth, or faster growth. Epidermal effacement (and therefore subsequent ulceration) might be caused by the action of metallo-

References


R. Corbalán-Vélez, a, *I. Oviedo-Ramírez, b E. Martínez-Barba, b A. Clemente-Ruiz de Almirón a

a Servicio de Dermatología, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain
b Servicio de Anatomía Patológica, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain

*Corresponding author.
E-mail address: raulcorb@gmail.com (R. Corbalán-Vélez).